Wall Street Journal -- With biopharmaceutical company MannKind awaiting word from the Food and Drug Administration on its key product candidate, an inhalable form of insulin, Chairman and Chief Executive Alfred Mann has spent more than $22 million in recent months to add to his already considerable holdings of company shares.
